Vitamin D Research

back to research menu

Hyperparathyroidism

• Markers of bone and calcium metabolism following gastric bypass and laparoscopic adjustable gastric banding. Obes Surg. 2008 Sep;18(9):1144–8.
• Vitamin D analogs: Therapeutic applications and mechanisms for selectivity. Mol Aspects Med. 2008 May 1.
• Hypovitaminosis D in obese children and adolescents: relationship with adiposity, insulin sensitivity, ethnicity, and season. Metabolism. 2008 Feb;57(2):183–91.
• Vitamin D supplementation has minor effects on parathyroid hormone and bone turnover markers in vitamin D-deficient bedridden older patients. Age Ageing. 2008 Jan;37(1):25–31.
• Changes in serum 25-hydroxyvitamin D and plasma intact PTH levels following treatment with ergocalciferol in patients with CKD. Am J Kidney Dis. 2007 Jul;50(1):59–68.
• A longitudinal study of serum 25-hydroxyvitamin D and intact PTH levels indicate the importance of vitamin D and calcium homeostasis regulation in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2007 Jun 19;.
• Effect of 2-Methylene-19-nor-(20S)-1alpha-Hydroxy- Bishomopregnacalciferol (2MbisP), an Analog of Vitamin D, on Secondary Hyperparathyroidism. J Bone Miner Res. 2007 May;22(5):686–94.
• Vitamin D and Parathyroid Hormone in Outpatients With Noncholestatic Chronic Liver Disease. Clin Gastroenterol Hepatol. 2007 Apr;5(4):513–20.
• Vitamin D analogs for secondary hyperparathyroidism: What does the future hold? J Steroid Biochem Mol Biol. 2007 Mar;103(3–5):578–83.
• Drug insight: vitamin D analogs in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease. Nat Clin Pract Endocrinol Metab. 2007 Feb;3(2):134–44. Review.
• Plasma 1,25-dihydroxyvitamin D levels in primary hyperparathyroidism depend on sex, body mass index, plasma phosphate and renal function. Clin Endocrinol (Oxf). 2007 Jan;66(1):35–42.
• Cross-sectional analysis of abnormalities of mineral homeostasis, vitamin D and parathyroid hormone in a cohort of pre-dialysis patients. The chronic renal impairment in Birmingham (CRIB) study. Nephron Clin Pract. 2007;107(3):c109–16.
• Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease. Am J Nephrol. 2007;27(1):36–43.
• Effects of parathyroidectomy on bone remodeling markers and vitamin D status in patients with chronic kidney disease-mineral and bone disorder. Int Urol Nephrol. 2007;39(4):1251–6.
• Relationships between Myocardial Injury, All-cause Mortality, Vitamin D, PTH, and Biochemical Bone Turnover Markers in Older Patients with Hip Fractures.Annals of Clinical and Laboratory Science 37:222–232 (2007).
• Synthesis and evaluation of a 3-position diastereomer of 1alpha,25-dihydroxy-2beta-(3-hydroxypropoxy)vitamin D(3) (ED-71). Bioorg Med Chem. 2006 Dec 1;14(23):8050–6.
• Routine oral calcium and vitamin D supplements for prevention of hypocalcemia after total thyroidectomy. American Journal of Surgery Volume 192, Issue 5, November 2006, Pages 675–678.
• Paricalcitol versus calcitriol treatment for hyperparathyroidism in pediatric hemodialysis patients. Pediatr Nephrol. 2006 Oct;21(10):1434–9.
• Postpartum vitamin D insufficiency and secondary hyperparathyroidism in healthy Danish women. Eur J Clin Nutr. 2006 Oct;60(10):1214–21.
• Optimal vitamin D status and serum parathyroid hormone concentrations in African American women. Am J Clin Nutr. 2006 Sep;84(3):602–9.
• Renal function and 25-hydroxyvitamin D concentrations predict parathyroid hormone levels in renal transplant patients. Nephrol Dial Transplant. 2006 Sep;21(9):2621–4.
• Regression of Skeletal Manifestations of Hyperparathyroidism with Oral Vitamin D. Journal of Clinical Endocrinology & Metabolism Vol. 91, No. 7 2480–2483
• Vitamin D physiology. Prog Biophys Mol Biol. 2006 Sep;92(1):4–8. Review.
• Plasma 25-hydroxyvitamin D and not 1,25-dihydroxyvitamin D is associated with parathyroid adenoma secretion in primary hyperparathyroidism: a cross-sectional study. Eur J Endocrinol. 2006 Aug;155(2):237–44.
• A very high incidence of low 25 hydroxy-vitamin D serum concentration in a French population of patients with primary hyperparathyroidism. J Endocrinol Invest. 2006 Jun;29(6):511–5.
• Effect of vitamin D supplementation on vitamin D status and bone turnover markers in young adults. Eur J Clin Nutr. 2006 Jun;60(6):727–33.
• The long-term effects of gastric bypass on vitamin D metabolism. Ann Surg. 2006 May;243(5):701–4; discussion 704–5.
• Addressing the musculoskeletal components of fracture risk with calcium and vitamin D: a review of the evidence. Calcif Tissue Int. 2006 May;78(5):257–70. Review.
• Molecular mechanism of 1,25-dihydroxyvitamin D3 inhibition of adipogenesis in 3T3-L1 cells. Am J Physiol Endocrinol Metab. 2006 May;290(5):E916–24.
• The prevalence of hypovitaminosis D and secondary hyperparathyroidism in obese Black Americans. Clin Endocrinol (Oxf). 2006 May;64(5):523–9.
• Neuropsychological function in relation to serum parathyroid hormone and serum 25-hydroxyvitamin D levels. The Tromso study. J Neurol. 2006 Apr;253(4):464–70.
• Vitamin D status of 51–75-year-old Irish women: its determinants and impact on biochemical indices of bone turnover. Public Health Nutr. 2006 Apr;9(2):225–33.
• Correlations between vitamin D status and biochemical/clinical and pathological parameters in primary hyperparathyroidism. World J Surg. 2006 Mar;30(3):321–6.
• Prospective study of perioperative factors predicting hypocalcemia after thyroid and parathyroid surgery. Arch Otolaryngol Head Neck Surg. 2006 Jan;132(1):41–5.
• Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation. Kidney Int. 2006 Jan;69(1):33–43. Review.
• Threshold value of serum 25-hydroxyvitamin D concentration in relation to elevated serum parathyroid hormone concentrations in elderly Japanese women. J Bone Miner Metab. 2006;24(5):395–400.
• Vitamin D and intact PTH status in patients with hip fracture. Osteoporos Int. 2006;17(11):1608–14.
• Causes of secondary hyperparathyroidism in a healthy population: the Tromso study. J Bone Miner Metab. 2006;24(1):58–64.
• 25-hydroxyvitamin D deficiency is a risk factor for symptoms of postoperative hypocalcemia and secondary hyperparathyroidism after minimally invasive parathyroidectomy. Surgery. 2005 Dec;138(6):1018–25; discussion 1025–6.
• Vitamin D, parathyroid hormone levels and bone mineral density in community-dwelling older women: the Rancho Bernardo Study. Osteoporos Int. 2005 Dec;16(12):1721–6.
• Inhibition of parathyroid hormone: a dose equivalency study of paricalcitol and doxercalciferol. Am J Nephrol. 2005 Nov–Dec;25(6):591–5.
• Relationship between serum parathyroid hormone levels, vitamin D sufficiency, and calcium intake. JAMA. 2005 Nov 9;294(18):2336–41.
• Vitamin D status, seasonal variations, parathyroid adenoma weight and bone mineral density in primary hyperparathyroidism. Clin Endocrinol (Oxf). 2005 Nov;63(5):506–13.
• Nutrition, mild hyperparathyroidism, and bone mineral density in young Japanese women. Am J Clin Nutr. 2005 Nov;82(5):1127–33.
• 25-hydroxyvitamin D levels and bone histomorphometry in hemodialysis renal osteodystrophy. Kidney Int. 2005 Oct;68(4):1840–8.
• Intravenous calcitriol for treatment of hyperparathyroidism in children on hemodialysis. Pediatr Nephrol. 2005 May;20(5):622–30.
• Prevalence of vitamin D insufficiency in postmenopausal south Indian women. Osteoporos Int. 2005 Apr;16(4):397–402.
• Parathyroid hormone decreases renal vitamin D receptor expression in vivo. Proc Natl Acad Sci U S A. 2005 Mar 29;102(13):4724–8.
• There is no lower threshold level for parathyroid hormone as 25-hydroxyvitamin D concentrations increase. J Endocrinol Invest. 2005 Feb;28(2):183–6. Review.
• Are low plasma levels of 25-(OH)vitamin D a major risk factor for hyperparathyroidism independent of calcitriol in renal transplant patients? J Nephrol. 2005 Jan–Feb;18(1):96–101.
• Low levels of 25-hydroxyvitamin D are associated with elevated parathyroid hormone in healthy adolescent females. Osteoporos Int. 2005 Jan;16(1):109–13.
• Comparisons between oral pulse alfacalcidol therapy and daily therapy in maintenance hemodialysis patients with secondary hyperparathyroidism: a randomized, controlled, and multicenter study. Ren Fail. 2005;27(2):205–12.
• Failure to normalize parathyroid hormone during treatment of vitamin D deficiency in Asian patients. Clin Endocrinol (Oxf). 2004 Nov;61(5):603–6.
• Serum parathyroid hormone level is associated with body mass index. The 5th Tromso study. Eur J Endocrinol. 2004 Aug;151(2):167–72.
• Supplementation with oral vitamin D3 and calcium during winter prevents seasonal bone loss: a randomized controlled open-label prospective trial. J Bone Miner Res. 2004 Aug;19(8):1221–30.
• The relationship between vitamin D and parathyroid hormone: calcium homeostasis, bone turnover, and bone mineral density in postmenopausal women with established osteoporosis. Bone. 2004 Jul;35(1):312–9.
• A randomised, controlled comparison of different calcium and vitamin D supplementation regimens in elderly women after hip fracture: The Nottingham Neck of Femur (NONOF) Study. Age Ageing. 2004 Jan;33(1):45–51.
• Bone density, parathyroid hormone, calcium and vitamin D nutritional status of institutionalized elderly subjects. J Nutr Health Aging. 2004;8(5):400–4.
• Effects of vitamin D supplementation on strength, physical function, and health perception in older, community-dwelling men. J Am Geriatr Soc. 2003 Dec;51(12):1762–7.
• Role of vitamin D and parathyroid hormone in the regulation of bone turnover and bone mass in men: the Minos study. Calcif Tissue Int. 2003 Dec;73(6):520–30.
• Association of low 25-hydroxyvitamin D concentrations with elevated parathyroid hormone concentrations and low cortical bone density in early pubertal and prepubertal Finnish girls. Am J Clin Nutr. 2003 Sep;78(3):485–92.
• The use in clinical practice of parathyroid hormone normative values established in vitamin D-sufficient subjects. J Clin Endocrinol Metab. 2003 Aug;88(8):3501–4.
• New vitamin D analogs. Kidney Int Suppl. 2003 Jun;(85):S83–7. Review.
• Vitamin D status and secondary hyperparathyroidism: the importance of 25-hydroxyvitamin D cut-off levels. Kidney Int Suppl. 2003 Jun;(85):S44–8.
• Vitamin D status and measurements of markers of bone metabolism in patients with small intestinal resection. Gut. 2003 May;52(5):653–8.
• Effects of calcitriol on parathyroid function and on bone remodelling in secondary hyperparathyroidism. Nephrol Dial Transplant. 2003 Apr;18(4):743–9.
• Age-related changes in the 25-hydroxyvitamin D versus parathyroid hormone relationship suggest a different reason why older adults require more vitamin D. J Clin Endocrinol Metab. 2003 Jan;88(1):185–91.
• Review of the concept of vitamin D "sufficiency and insufficiency." Nefrologia. 2003;23 Suppl 2:73–7. Review.
• Deletion of deoxyribonucleic acid binding domain of the vitamin D receptor abrogates genomic and nongenomic functions of vitamin D. Mol Endocrinol. 2002 Jul;16(7):1524–37.
• Vitamin D analogs: new therapeutic agents for secondary hyperparathyroidism. Treat Endocrinol. 2002;1(5):313–27. Review.
• Vitamin D analogues for secondary hyperparathyroidism. Nephrol Dial Transplant. 2002;17 Suppl 10:10–9. Review.
• Vitamin D analogs for the treatment of secondary hyperparathyroidism. Blood Purif. 2002;20(1):109–12. Review.
• Vitamin D analogues for the management of secondary hyperparathyroidism. Am J Kidney Dis. 2001 Nov;38(5 Suppl 5):S34–40. Review.
• Hypovitaminosis D and "functional hypoparathyroidism"—the NoNoF (Nottingham Neck of Femur) study. Age Ageing. 2001 Nov;30(6):467–72.
• Seasonal variations in serum levels of 25-hydroxyvitamin D and parathyroid hormone but no detectable change in femoral neck bone density in an older population with regular outdoor exposure. J Am Geriatr Soc. 2001 Sep;49(9):1190–6.
• Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev. 2001 Aug;22(4):477–501. Review.
• Vitamin D status and its adequacy in healthy Danish perimenopausal women: relationships to dietary intake, sun exposure and serum parathyroid hormone. Br J Nutr. 2001 Aug;86 Suppl 1:S97–103.
• Vitamin D status affects serum parathyroid hormone concentrations during winter in female adolescents: associations with forearm bone mineral density. Am J Clin Nutr. 2001 Aug;74(2):206–10.
• Vitamin D status and redefining serum parathyroid hormone reference range in the elderly. J Clin Endocrinol Metab. 2001 Jul;86(7):3086–90.
• A global study of vitamin D status and parathyroid function in postmenopausal women with osteoporosis: baseline data from the multiple outcomes of raloxifene evaluation clinical trial. J Clin Endocrinol Metab. 2001 Mar;86(3):1212–21.
• Wintertime vitamin D deficiency in male adolescents: effect on parathyroid function and response to vitamin D3 supplements. Osteoporos Int. 2001;12(10):875–9.
• Effect of calcitriol treatment and withdrawal on hyperparathyroidism in haemodialysis patients with hypocalcaemia. Nephrol Dial Transplant. 2001 May;16(5):1009–16.
• Serum 25-hydroxyvitamin D and parathyroid hormone in patients with ankylosing spondylitis before and after a three-week rehabilitation treatment at high altitude during winter and spring. Wien Klin Wochenschr. 2001 Apr 30;113(9):328–32.
• A global study of vitamin D status and parathyroid function in postmenopausal women with osteoporosis: baseline data from the multiple outcomes of raloxifene evaluation clinical trial. J Clin Endocrinol Metab. 2001 Mar;86(3):1212–21.
• Circaannual rhythms and interactions of vitamin D metabolites, parathyroid hormone, and biochemical markers of skeletal homeostasis: a prospective study. J Bone Miner Res. 2000 Dec;15(12):2443–50.
• Summer/winter differences in the serum 25-hydroxyvitamin D3 and parathyroid hormone levels of Japanese women. Int J Biometeorol. 2000 Nov;44(4):186–9.
• Vitamin D insufficiency and hyperparathyroidism in a low income, multiracial, elderly population. J Clin Endocrinol Metab. 2000 Nov;85(11):4125–30.
• Vitamin D status: effects on parathyroid hormone and 1, 25-dihydroxyvitamin D in postmenopausal women. Am J Clin Nutr. 2000 Jun;71(6):1577–81.
• Severe myopathy associated with vitamin D deficiency in western New York. Arch Intern Med. 2000 Apr 24;160(8):1199–203.
• Effect of vitamin D nutrition on parathyroid adenoma weight: pathogenetic and clinical implications. J Clin Endocrinol Metab. 2000 Mar;85(3):1054–8.
• Prevention of vitamin D deficiency in adolescents and pre-adolescents. An interventional multicenter study on the biological effect of repeated doses of 100,000 IU of vitamin D3. Arch Pediatr. 2000 Feb;7(2):148–53. In French.
• Vitamin D analogs: perspectives for treatment. Miner Electrolyte Metab. 1999 Jul–Dec;25(4–6):337–41. Review.
• Parathyroid function as a determinant of the response to calcitriol treatment in the hemodialysis patient. Kidney Int. 1999 Jul;56(1):306–17.
• Vitamin D status, parathyroid function and femoral bone density in an elderly Swedish population living at home. Aging (Milano). 1999 Jun;11(3):200–7.
• Is low plasma 25-(OH)vitamin D a major risk factor for hyperparathyroidism and Looser's zones independent of calcitriol? Kidney Int. 1999 Jun;55(6):2169–77.
• Suppression of parathyroid hormone secretion in hemodialysis patients by a novel vitamin D analogue: 19-nor-1,25-dihydroxyvitamin D2. Am J Kidney Dis. 1998 Oct;32(2 Suppl 2):S48–54.
• Ultraviolet irradiation corrects vitamin D deficiency and suppresses secondary hyperparathyroidism in the elderly. J Bone Miner Res. 1998 Aug;13(8):1238–42.
• 19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol. 1998 Aug;9(8):1427–32.
• High prevalence of vitamin D deficiency and reduced bone mass in Parkinson's disease. Neurology. 1997 Nov;49(5):1273–8.
• A crossover comparison of intermittent oral and intravenous administration of calcitriol on the parathyroid hormone concentration in hemodialysis patients. Miner Electrolyte Metab. 1997;23(1):13–8.
• Plasma calcidiol, season, and serum parathyroid hormone concentrations in healthy elderly men and women. Am J Clin Nutr. 1997 Jan;65(1):67–71.
• Importance of albumin, 25(OH)-vitamin D and IGFBP-3 as risk factors in elderly women and men with hip fracture. Osteoporos Int. 1997;7(5):457–62.
• Long-term effects of intravenous calcitriol therapy on the control of secondary hyperparathyroidism. Am J Kidney Dis. 1996 Nov;28(5):704–12.
• Effect of parathyroid hormone (hPTH[1–34]) infusion on serum 1,25-dihydroxyvitamin D and parathyroid hormone in normal women. J Bone Miner Res. 1996 Oct;11(10):1400–5.
• Calcitriol and the parathyroid hormone-ionized calcium curve: a comparison of methodologic approaches. J Am Soc Nephrol. 1996 Mar;7(3):497–505.
• Different effects of calcitriol and parathyroidectomy on the PTH-calcium curve in dialysis patients with severe hyperparathyroidism. Nephrol Dial Transplant. 1996 Jan;11(1):81–7.
• Bone density, vitamin D nutrition, and parathyroid hormone levels in women with dementia. J Am Geriatr Soc. 1995 Oct;43(10):1088–91.
• Single-dose cholecalciferol suppresses the winter increase in parathyroid hormone concentrations in healthy older men and women: a randomized trial. Am J Clin Nutr. 1994 May;59(5):1040–4.
• Suppression of secondary hyperparathyroidism in chronic dialysis patients by single oral weekly dose of 1,25-dihydroxy cholecalciferol. Intern Med. 1993 Sep;32(9):695–701.
• Secondary hyperparathyroidism in elderly people: combined effect of renal insufficiency and vitamin D deficiency. Am J Clin Nutr. 1993 Aug;58(2):187–91.
• Improvement of secondary hyperparathyroidism and reduction of the set point of calcium after intravenous calcitriol. Kidney Int Suppl. 1993 Jun;41:S125–30.
• Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med. 1992 Dec 3;327(23):1637–42.
• Influence of vitamin D on parathyroid function in the elderly. J Clin Endocrinol Metab. 1992 Aug;75(2):494–501.
• Determinants of intact parathyroid hormone and free 1,25-dihydroxyvitamin D levels in mild and moderate renal failure. Nephron. 1992;61(4):422–7.
• Effect of chronic intravenous calcitriol on parathyroid function and set point of calcium in dialysis patients with refractory secondary hyperparathyroidism. Nephrol Dial Transplant. 1992;7(8):822–8.
• The effect of long-term intravenous calcitriol administration on parathyroid function in hemodialysis patients. J Am Soc Nephrol. 1991 Nov;2(5):1014–20.
• The 'oral 1,25-dihydroxyvitamin D3 pulse therapy' in hemodialysis patients with severe secondary hyperparathyroidism. Nephron. 1991;57(1):23–8.
• Vitamin D status, parathyroid hormone and sunlight in Turkish, Moroccan and Caucasian children in The Netherlands. Eur J Clin Nutr. 1990 Jun;44(6):461–70.
• Direct inhibitory effect of calcitriol on parathyroid function (sigmoidal curve) in dialysis. Kidney Int. 1989 Dec;36(6):1093–8.
• Hyperparathyroidism and 1,25-dihydroxyvitamin D deficiency in mild, moderate, and severe renal failure. J Clin Endocrinol Metab. 1988 Nov;67(5):876–81.
• Influence of cadmium on the metabolism of vitamin D3 in rats. Toxicol Appl Pharmacol. 1987 Jun 30;89(2):158–64.
• The effect of vitamin D on bone in vivo. Endocrinology. 1986 Jun;118(6):2217–24.
• Serum phosphate, parathyroid hormone and vitamin D metabolites in patients with chronic renal failure: effect of aluminum hydroxide administration. Nephron. 1985;40(3):286–91.
• Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients. J Clin Invest. 1984 Dec;74(6):2136–43.
• Effect of dietary phosphorus on circulating concentrations of 1,25-dihydroxyvitamin D and immunoreactive parathyroid hormone in children with moderate renal insufficiency. J Clin Invest. 1984 Jun;73(6):1580–9.

back to research menu